Transpyloric Feeding for Very Low Birth Weight Infants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the safety and effectiveness of a special feeding method for very small premature infants. The focus is on duodenal feeds, which deliver food directly to the intestine and may reduce lung problems caused by stomach reflux. Researchers aim to determine if this method can safely assist infants who struggle with traditional feeding due to their small size and early birth. Infants admitted to a specific NICU with a birth weight under 1251 grams may qualify as candidates. As an unphased study, this trial provides a unique opportunity to contribute to innovative research that could enhance feeding methods for premature infants.
Will I have to stop taking my current medications?
The trial information does not specify whether participants must stop taking their current medications.
What prior data suggests that transpyloric feeding is safe for very low birth weight infants?
Research has shown that feeding directly into the small intestine, known as transpyloric feeding, is safe for very low birth weight infants. Studies suggest this method can reduce breathing pauses (apnea) and slow heart rates (bradycardia) in premature babies. It can also lessen the need for machines to assist with breathing and may lower the risk of lung problems like bronchopulmonary dysplasia. Overall, transpyloric feeding serves as a safe alternative to traditional feeding methods, especially when using human milk.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores a new feeding technique for very low birth weight infants. Unlike the standard gastric feeding method, which delivers nutrition to the stomach, this trial is investigating duodenal feeding, where nutrients are delivered directly to the duodenum, a part of the small intestine. This approach could potentially improve nutrient absorption and digestion, bypassing the stomach and reducing the risk of complications like reflux. By comparing these two methods, researchers hope to find out if duodenal feeding offers significant benefits in terms of growth and overall health for these fragile infants.
What evidence suggests that transpyloric feeding is effective for very low birth weight infants?
Research has shown that feeding preterm infants directly into the small intestine, known as transpyloric feeding, can reduce breathing pauses and slow heart rates. In this trial, participants in the "Duodenal Feeds" arm will receive feeds via this experimental route. This method is particularly beneficial for newborns at high risk, such as those with very low birth weight. By bypassing the stomach, it reduces the risk of food refluxing into the lungs, which can be harmful. However, concerns exist about potential risks, such as difficulty digesting food and necrotizing enterocolitis, a serious intestinal disease. Overall, feeding directly into the small intestine appears promising for improving breathing and heart rate stability in preterm infants.15678
Who Is on the Research Team?
Noura Nickel, MD
Principal Investigator
Johns Hopkins All Children's Hospital
Are You a Good Fit for This Trial?
This trial is for premature infants weighing less than 1251 grams at birth, admitted to the NICU within 72 hours of life. It's not suitable for babies who haven't started feeding by day 10, those on certain medications, with growth restrictions, very low APGAR scores, intestinal issues or congenital anomalies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants are randomized to receive either duodenal or gastric feeds once they advance past 50mL/kg/day of enteral feeds.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including primary and secondary outcomes.
What Are the Treatments Tested in This Trial?
Interventions
- Mode of Delivery of Feeds
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins All Children's Hospital
Lead Sponsor